G. Montalban-Bravo

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

This study shows MDS hematopoietic stem cells reprogram their differentiation state to bypass venetoclax sensitivity through genetic mutations and transcriptional changes.

This study identifies MCL1 as a survival factor in RAS-mutated CMML, explaining resistance to BCL2 inhibitors and suggesting new therapeutic targets.

This study identifies DNA2 as a key factor in mitochondrial metabolism that enables multiple myeloma cells to survive DNA damage, showing that targeting DNA2 overcomes metabolic reprogramming and enhances therapy effectiveness.

This study examines clinicopathologic features and treatment outcomes in 65 patients with atypical chronic myeloid leukemia, identifying key mutations and predictors of survival.

This study shows that SF3B1 mutations specifically at codon K700E, but not other codons, are independently linked to better overall survival in myelodysplastic syndromes.